Shots:
- Italfarmaco has entered into an exclusive licensing agreement with JCR Pharmaceuticals for the development and commercialisation of givinostat in Japan
- As per the deal, JCR will secure exclusive rights to commercialize givinostat, marketed as Duvyzat in US, EU & UK, for Duchenne muscular dystrophy (DMD) in Japan & will lead local execution of clinical development efforts & regulatory submissions
- The partnership also includes strategic rare disease collaboration to strengthen both portfolios by exploring joint development opportunities across JCR’s R&D pipeline & platform technologies
Ref: Business Wire | Image: JCR & Italfarmaco | Press Release
Related News: JCR Pharmaceuticals Collaborates with Acumen Pharmaceuticals to Develop Novel Alzheimer’s Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
